SI3391890T1 - Formulacije intravenske raztopine posakonazola, stabilizirane s substituiranim beta-ciklodekstrinom - Google Patents

Formulacije intravenske raztopine posakonazola, stabilizirane s substituiranim beta-ciklodekstrinom

Info

Publication number
SI3391890T1
SI3391890T1 SI201132006T SI201132006T SI3391890T1 SI 3391890 T1 SI3391890 T1 SI 3391890T1 SI 201132006 T SI201132006 T SI 201132006T SI 201132006 T SI201132006 T SI 201132006T SI 3391890 T1 SI3391890 T1 SI 3391890T1
Authority
SI
Slovenia
Prior art keywords
cyclodextrin
intravenous solution
solution formulations
substituted beta
formulations stabilized
Prior art date
Application number
SI201132006T
Other languages
English (en)
Inventor
Susan K. Heimbecher
David Monteith
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3391890(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of SI3391890T1 publication Critical patent/SI3391890T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201132006T 2010-06-29 2011-06-24 Formulacije intravenske raztopine posakonazola, stabilizirane s substituiranim beta-ciklodekstrinom SI3391890T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35970110P 2010-06-29 2010-06-29
EP18171672.1A EP3391890B1 (en) 2010-06-29 2011-06-24 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin

Publications (1)

Publication Number Publication Date
SI3391890T1 true SI3391890T1 (sl) 2021-11-30

Family

ID=45441500

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201132006T SI3391890T1 (sl) 2010-06-29 2011-06-24 Formulacije intravenske raztopine posakonazola, stabilizirane s substituiranim beta-ciklodekstrinom

Country Status (20)

Country Link
US (2) US9023790B2 (sl)
EP (3) EP3960185A1 (sl)
JP (1) JP6008849B2 (sl)
KR (1) KR101834024B1 (sl)
CN (2) CN107049935A (sl)
AU (1) AU2011276680B2 (sl)
BR (1) BR112012033077B8 (sl)
CA (1) CA2802929C (sl)
CY (1) CY1124690T1 (sl)
DK (1) DK3391890T3 (sl)
ES (1) ES2893444T3 (sl)
HR (1) HRP20211686T1 (sl)
HU (1) HUE056581T2 (sl)
LT (1) LT3391890T (sl)
MX (2) MX338685B (sl)
PL (1) PL3391890T3 (sl)
PT (1) PT3391890T (sl)
RS (1) RS62583B1 (sl)
SI (1) SI3391890T1 (sl)
WO (1) WO2012005973A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
MX338685B (es) 2010-06-29 2016-04-26 Merck Sharp & Dohme Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida.
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
CN104271605B (zh) 2012-02-15 2017-07-25 锡德克斯药物公司 环糊精衍生物的制造方法
SG11201602596UA (en) 2013-10-03 2016-04-28 Dow Pharmaceutical Sciences Stabilized efinaconazole compositions
CN104546724A (zh) * 2013-10-12 2015-04-29 博瑞生物医药技术(苏州)有限公司 一种抗真菌药的固体分散体
EP3071295A4 (en) 2013-11-22 2017-05-31 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices
CN105879041A (zh) * 2014-11-14 2016-08-24 北京赛林泰医药技术有限公司 一种泊沙康唑口服液及其制备方法
WO2016079749A2 (en) * 2014-11-19 2016-05-26 Gufic Biosciences Limited Process for preparation of parenteral formulation of anidulafungin
CN104473871B (zh) * 2014-11-28 2017-03-08 济南康和医药科技有限公司 一种泊沙康唑脂肪乳注射液及其制备方法
CN106265534A (zh) * 2015-05-25 2017-01-04 江苏正大丰海制药有限公司 一种泊沙康唑冻干粉针剂的制备方法
CN106511262A (zh) * 2015-09-11 2017-03-22 上海美悦生物科技发展有限公司 一种泊沙康唑口服溶液剂及其制备方法
CN107033186B (zh) 2016-02-04 2020-06-09 武汉朗来科技发展有限公司 泊沙康唑衍生物、其药物组合物和用途
EP3541364A1 (en) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
CN110711174A (zh) * 2018-07-11 2020-01-21 郑州泰丰制药有限公司 一种泊沙康唑注射液中间体溶液配制方法
TR201820816A2 (tr) * 2018-12-28 2020-07-21 Polifarma Ilac Sanayi Ve Ticaret Anonim Sirketi Si̇klodekstri̇n ve şeker i̇çeren stabi̇l enjekte edi̇lebi̇li̇r posakonazol formülasyonlari
EP4161515A4 (en) * 2020-06-06 2024-08-07 Invengene Ltd STABLE LIQUID POSACONAZOLE COMPOSITIONS
WO2023148763A1 (en) * 2022-02-01 2023-08-10 Cipla Limited Injectable pharmaceutical compositions of azole antifungal agents

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5257985A (en) 1989-12-04 1993-11-02 Richard Puhl Multi-chamber intravenous bag apparatus
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ES2159623T3 (es) 1993-12-21 2001-10-16 Schering Corp Antifungicos de tetrahidrofurano.
US5661151A (en) 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
US6713481B1 (en) 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
ES2334657T3 (es) 2002-04-30 2010-03-15 Otsuka Pharmaceutical Factory, Inc. Contenedor medico con multiples camaras y bolsa destinada a encerrarlo.
BRPI0411043A (pt) * 2003-06-06 2006-07-11 Sankyo Co composição medicinal
US20060160823A1 (en) 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
AR049063A1 (es) * 2004-05-28 2006-06-21 Schering Corp Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
PL1776109T3 (pl) * 2004-08-13 2009-06-30 Schering Plough Ltd Farmaceutyczna formulacja zawierająca antybiotyk, triazol i kortykosteroid
JP4953018B2 (ja) * 2005-03-15 2012-06-13 味の素株式会社 薬剤移送具
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN101370453B (zh) * 2005-12-14 2013-12-18 努沃研究公司 用于皮肤输送药物的组合物和方法
US20070281011A1 (en) * 2006-05-30 2007-12-06 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
US20080194519A1 (en) * 2006-09-15 2008-08-14 Regents Of The University Of Minnesota Topiramate compositions and methods for their use
JP2010515762A (ja) 2007-01-16 2010-05-13 エンゾン ファーマスーティカルズ インコーポレイテッド ポサコナゾール−ポリマー複合体、並びに、ポサコナゾールおよびそのポリマー複合体を使用した治療方法
WO2009018069A2 (en) 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US7863309B2 (en) * 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
MX338685B (es) 2010-06-29 2016-04-26 Merck Sharp & Dohme Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida.

Also Published As

Publication number Publication date
US9023790B2 (en) 2015-05-05
JP2013535422A (ja) 2013-09-12
LT3391890T (lt) 2021-11-10
CY1124690T1 (el) 2022-07-22
CN102958528A (zh) 2013-03-06
EP3960185A1 (en) 2022-03-02
EP3391890B1 (en) 2021-08-25
CA2802929C (en) 2019-01-08
KR101834024B1 (ko) 2018-03-02
AU2011276680A1 (en) 2012-12-06
KR20130114603A (ko) 2013-10-17
CA2802929A1 (en) 2012-01-12
CN107049935A (zh) 2017-08-18
BR112012033077B8 (pt) 2023-04-25
AU2011276680B2 (en) 2014-07-17
RS62583B1 (sr) 2021-12-31
HUE056581T2 (hu) 2022-02-28
EP2588116A4 (en) 2013-12-04
MX338685B (es) 2016-04-26
JP6008849B2 (ja) 2016-10-19
PT3391890T (pt) 2021-10-14
EP3391890A1 (en) 2018-10-24
HRP20211686T1 (hr) 2022-03-04
US9358297B2 (en) 2016-06-07
MX346901B (es) 2017-04-04
PL3391890T3 (pl) 2021-12-20
MX2012015168A (es) 2013-01-24
BR112012033077A2 (pt) 2016-11-22
EP2588116A1 (en) 2013-05-08
US20130096053A1 (en) 2013-04-18
ES2893444T3 (es) 2022-02-09
RU2013103724A (ru) 2014-08-10
US20150265715A1 (en) 2015-09-24
DK3391890T3 (da) 2021-11-01
WO2012005973A1 (en) 2012-01-12
BR112012033077B1 (pt) 2020-01-21

Similar Documents

Publication Publication Date Title
HUE056581T2 (hu) Szubsztituált béta-ciklodextrinnel stabilizált pozakonazol intravénás oldat formulációk
IL246205A0 (en) History of heteroarylpiperidine and piperazine as fungicides
IL232345A0 (en) A stable preparation for pest control
EP2747556A4 (en) PYRETHROID FORMULATIONS
IL224690A (en) History of heteroarylpipridine and piperazine as fungicides
HUE042850T2 (hu) Készítmények hatóanyag szállításra
EP2629786A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS
HK1243004A1 (zh) 輸液製劑
ZA201402453B (en) Insecticidal 2-methoxybenzamide derivatives
ZA201207375B (en) Stabilized pharmaceutical composition
EP2769718A4 (en) MEDICINAL COMPOSITION
PT2739276T (pt) Composição antisséptica
EP2654872A4 (en) AUTODILATION CANNULA
ZA201302012B (en) Low dose pharmaceutical composition
ZA201305986B (en) Improved insecticide formulations
EP2683746A4 (en) OLIGOSACCHARIDE COMPOUNDS
EP2524698A4 (en) INSULIN PRODUCTION
PL2558470T3 (pl) Pochodne ditiinopirydazynodionu jako środki grzybobójcze
IL267880A (en) History of heteroarylpiperidine and piperazine as fungicides
AU4553P (en) WES04 Westringia fruticosa
GB201108498D0 (en) Agricultural composition
PL391402A1 (pl) Kaniula dezintegrująco-ssąca
GB201000727D0 (en) Improved nappy
GB201001317D0 (en) Medicament
HUP1000033D0 (en) Novel compounds with medicinal effect